Drug Profile
Hib-DTaP-poliovirus vaccine - GSK
Alternative Names: Cinquerix; DTPa-IPV-Hib; Hib-DTP-acellular-poliovirus vaccine - GSK; Infanrix IPV Hib; Infanrix-IPV-HiBLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Bacterial vaccines; Haemophilus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 04 Jun 2015 No recent reports of development identified - Phase-III for Diphtheria (In infants, Prevention) in China (IM)
- 04 Jun 2015 No recent reports of development identified - Phase-III for Haemophilus infections (In infants, Prevention) in China (IM)
- 04 Jun 2015 No recent reports of development identified - Phase-III for Pertussis (In infants, Prevention) in China (IM)